Hepa-B is indicated for active immunization against infection caused by all known subtypes of Hepa-B B virus. As Hepa-B D (caused by the delta virus) does not occur in the absence of Hepa-B B infection, it can be expected that Hepa-B D will also be prevented by Hepa-B B vaccination ... Read more Hepa-B is indicated for active immunization against infection caused by all known subtypes of Hepa-B B virus. As Hepa-B D (caused by the delta virus) does not occur in the absence of Hepa-B B infection, it can be expected that Hepa-B D will also be prevented by Hepa-B B vaccination. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to Hepa-B B virus, for example: A baby whose mother is infected can be infected at birth. Children, adolescents, and adults can become infected by: Contact with blood and body fluids through breaks in the skin such as bites, cuts, or sores Contact with objects that have blood or body fluids on them such as toothbrushes, razors or monitoring and treatment devices for diabetes Having unprotected sex with an infected person Sharing needles when injecting drugs Being stuck with a used needle Household contacts of people infected with Hepa-B B Residents and staff in institutions for the developmental^ disabled Kidney dialysis patients People who travel to countries where Hepa-B B is common People with HIV infection Persons with hemophilia, thalassemia, sickle cell anemia, cirrhosis Military personnel identified as being at increased risk. Morticians and Embalmers. Prisoners. Users of illicit injectable drugs. Others: Police, fire department personnel, who render first aid or medical assistance, and any others who, through their work or personal life-style, may be exposed to the Hepa-B B virus.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
First dose: at the appropriate date Second dose: 1 month after first dose Third dose: 2 months after first dose Fourth dose: 6 months after first dose Immunization schedule and booster doses may need to be adjusted in those with low antibody concentration. Booster vaccinations : For persons with normal immune status who have been vaccinated, booster doses of Hepatitis B vaccine has not been established. However, booster doses are recommended for hemodialysis patients or other immunocompromised persons.
Hepa-B is generally well tolerated. Most recipients of Hepa-B experience some reactions upon vaccination. These are generally moderate and short. They mainly consist of local reactions at the injection site (erythema, induration and tenderness). Systemic reactions (malaise, headache, diarrhea, vomiting, myalgia and elevated temperature) are reported less commonly. In very rare cases allergic type reactions (pruritus, rash, urticaria) may be observed.
Hypersensitivity to any component of the vaccine, including yeast, is a contraindication. This vaccine is contraindicated in patients with previous hypersensitivity to any Hepatitis B virus containing vaccine.